SpringWorks cancelled from conference this week, says Barclays

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following cancellations from other public events since the neurofibromatosis type one approval on February 11. SpringWorks has not held discussions with analysts and investors, and a potential deal announcement remains pending, the analyst tells investors in a research note. Barclays points out that some investors had penciled in today’s Merck KGaA’s (MKGAY) (MKGAY earnings as a potential catalyst for a deal announcement. There was no update on Merck KGaA’s earnings press release this morning, it adds. Barclays continues to see limited regulatory risk for Merck KGaA’s potential buyout of SpringWorks. It has an Overweight rating on SpringWorks with a $63 price target